Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET

Company Participants

Diantha Duvall - Chief Financial Officer

Jim Dentzer - President & Chief Executive Officer

Conference Call Participants

Yale Jen - Laidlaw & Co.

Operator

Good morning, and welcome to Curis' Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode. [Operator Instructions] After the company's prepared remarks, all participants will have an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded.

I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer, Diantha, please go ahead.

Diantha Duvall

Thank you, and welcome to Curis’ third quarter 2023 business update call. Before we begin, I’d like to encourage everyone to go to the Investors section of our website at www.curis.com to find our third quarter 2023 business update press release and related financial tables.

I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ materially. For additional details, please see our SEC filings.

Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; and Jonathan Zung, our Chief Development Officer. We will also be available for a question-and-answer period at the end of our call.

I'd now like to turn the call over to Jim.

Jim Dentzer

Thank you, Diantha. Good morning, everyone, and welcome to Curis' third quarter business update call. This quarter marked a key inflection point for the company and for patients as we were able to return our focus to clinical enrollment in our TakeAim Leukemia and TakeAim Lymphoma studies with the removal of the partial clinical hold.

Later this morning, abstracts for the 65th ASH Annual Meeting will be unveiled, and we are pleased to have several abstracts under consideration. At ASH, we expect to provide an update from our TakeAim Lymphoma study, including our first look at proof-of-concept data for patients with primary CNS lymphoma, a rare form of extranodal non-Hodgkin lymphoma, for which there are limited treatment options.

In the TakeAim Leukemia study, we have reopened our clinical sites and are working with them to identify and enroll new patients. As a reminder, the TakeAim Leukemia study is a monotherapy study, targeting patients with relapsed or refractory AML with either a FLT3 or spliceosome mutation. Enrollment of new patients has begun, and we expect to have our first look at data from these patients in the first half of 2024.